Article

Regulation of cosmetic contact lenses pursued

Washington, DC—The American Academy of Ophthalmology (AAO) has renewed its fight to regulate cosmetic plano contact lenses. A bill introduced in Congress on Jan. 26 would amend the Federal Food, Drug and Cosmetic Act to recognize and regulate both corrective and non-corrective contact lenses as medical devices, regardless of their intended use.

Washington, DC-The American Academy of Ophthalmology (AAO) has renewed its fight to regulate cosmetic plano contact lenses. A bill introduced in Congress on Jan. 26 would amend the Federal Food, Drug and Cosmetic Act to recognize and regulate both corrective and non-corrective contact lenses as medical devices, regardless of their intended use.

Similar legislation was introduced last session and was passed by the House of Representatives by a unanimous vote, but died in a Senate committee. Reps. John Boozman (R-AR) and Henry Waxman (D-CA) are the original co-sponsors of the House bill.

Sens. Michael DeWine (R-OH) and Edward Kennedy are the original co-sponsors of the Senate bill.

"The unsupervised, unregulated, and unmonitored use of contact lenses is a recipe for disaster," said Thomas L. Steinemann, MD, an AAO member and associate professor of ophthalmology at Case Western Reserve University.

Dr. Steinemann authored a case report of six patients treated for complications related to these lenses that appeared in the October 2003 issue of Eye Contact Lens. Two of his patients developed blinding complications, requiring lengthy hospital stays. One 14-year-old patient needed a corneal transplant after wearing cosmetic lenses without the supervision of an eye-care professional. The other patient remains legally blind. In another 11 cases that he documented, three developed blinding complications requiring hospitalization.

Although the FDA has ordered customs officials to detain all decorative contact lenses entering the United States, AAO leaders believe that a legislative fix is the best long-term solution to this problem.

"We are hopeful that we will get the job done in this Congressional session," said Catherine Cohen, AAO vice president for governmental affairs.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.